Share this article
Share this article
SEATTLE, Jan. 12, 2021 /PRNewswire/ Safeology™ (www.safeology.com), founded in response to the COVID-19 pandemic, has made an important scientific breakthrough that offers a clear path to making public spaces safer and significantly reducing the risk of COVID-19 transmission. Safeology has pioneered the use of UVC light fixtures to remove 99.9% of COVID-19 from the air and surfaces – the gold standard in fighting a viral outbreak.
Safeology products include UVC Towers, UVC Mobile Air Purifiers, and Upper Room UVC Fixtures. The UVC Towers provide disinfection on demand for surface-based viruses and pathogens. The UVC Mobile Air Purifiers include both UVC light and HEPA filters to create the cleanest, safest air possible. And the Upper Room UVC Fixtures provide safe, continual virus inactivation as the air circulates, providing effective eradication of viruses even when people are present in the space.
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform Transaction bolsters development of AuraVax s lead COVID-19 intranasal vaccine and strengthens platform for therapeutic development targeting a range of viral infections
News provided by
Share this article
Share this article
HOUSTON, Jan. 13, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, today announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists by Mei X. Wu, PhD, of the Wellman Center for Photomedicine at MGH. Research related to this technology was published in
NurseNow Staffing Joins Decentralized Trials & Research Alliance (DTRA) To Democratize And Accelerate Clinical Trials
New Global Industry Coalition That Aims to Dramatically Increase Access for All Patients Populations in Clinical Trials and Research Launches Today
News provided by
Share this article
Share this article
MAUMEE, Ohio, Jan. 13, 2021 /PRNewswire/ NurseNow Staffing is pleased to announce becoming a founding member of an historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (
DTRA), which launched December 10th, 2020, unites industry stakeholders, including healthcare companies, regulators, patient groups, and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinica
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.
The collaboration will combine Sosei Heptares world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability, with PharmEnable s proprietary advanced artificial intelligence (AI)-enabled and medicinal chemistry technologies (ChemUniverse and ChemSeek) to identify novel, highly specific drug leads for further development.
Share this article
STOCKHOLM, Jan. 12, 2021 /PRNewswire/
Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases will be given by Professor Jeff Evans, Director of Institute of Cancer Sciences at University of Glasgow, at the virtual ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The presentation will be given on January 15, 2021, at 2 pm CET during the Hepatobiliary Cancer session (presentation number 309).
The results from the completed phase Ia intra-patient dose escalation part of the study show that MIV-818 has an acceptable safety and tolerability profile and a selective effect on liver cancer cells. The inter-patient dose escalation phase Ib part is currently ongoing at a dose of 40 mg for 5 days in 21-day cycles.